Colestasis: un enfoque actualizado

Sergio Del Valle Díaz, Marjoris Piñera Martínez, Novelia Medina González, Juan Sánchez Vega

Texto completo:

PDF HTML

Resumen

Mediante una extensa revisión bibliográfica fue posible profundizar en el tema de las ictericias obstructivas o las colestasis, sobre todo en los aspectos más importantes de su definición, semiogénesis, clasificación, etiopatogenia, manifestaciones clínicas, estudios de laboratorio e imagenológicos, además del diagnóstico, la evolución, el pronóstico y tratamiento, con el objetivo de proporcionar los elementos más novedosos de cada uno de ellos, a través de un enfoque didáctico y una base científica, desde la óptica del internista, para así facilitar conocimientos prácticos acerca del síndrome.

Palabras clave

ictericia obstructiva, colestasis, colestasis intrahepáticas, colestasis extrahepáticas, hiperbilirrubinemia.

Referencias

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2): 237-67.

Maria Saracco G, Evangelista A, Fagoonee S, Ciccone G, Bugianesi E, Caviglia GP, et al. Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014. World J Gastroenterol. 2016; 22(36): 8187-93.

Mayo MJ. Cholestasis liver disease overlap syndromes. Clin Liver Dis. 2013; 17 () 243–253.

Delemos AS, Friedman LS. Systemic causes of cholestasis. Clin Liver Dis. 2013; 17(2): 301–17.

Socorras Cortada Y, Vera López RF, Vera Mosqueda D. Comportamiento del íctero obstructivo extrahepático en los hospitales “V. I. Lenin” y “Lucía Iñiguez Landín”. Holguín. 2002-2005. Corr Med Cient Holg 2006 [citado 7 May 2017]; 10(2). Disponible en: http://www.cocmed.sld.cu/no102/n102ori4.htm

Klimovskij M, Dulskas A, Kraulyte Z, Mikalauskas S. Ascariasis of the pancreatic duct. BMJ Case Rep. 2015; 2015: 2014-79.

Gibor U, Perry ZH, Netz U, Glazer Y, Laufer L, Kirshtein B. CA 19-9 in the presence of obstructive jaundice due to Mirizzi syndrome. Isr Med Assoc J. 2015; 17(1): 60-1.

Vilella Al, Limsuwat C, Williams DR, Seifert DF. Cholestatic jaundice as a result of combination designer supplement ingestion. Ann Pharmacother. 2013; 47(7-8): e33

Martínez Montero I, Segura Ortega V, Martínez Jiménez L, García Jiménez A, Unzetabarrenetxea Barrenetxea O, Pérez Rodríguez AF. Cholestasis and listeriosis in the third trimester of pregnancy. An Sist Sanit Navar. 2013; 36(3): 569-75.

Jun Y, Ya-Li Y, Yu Jin, Ying Z, Chang-Qing Z. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. World J Gastroenterol. 2016; 22(33): 7579-86.

Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA., et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014; 46(4): 326-8.

Khoo A. Acute cholestatic hepatitis induced by Epstein–Barr virus infection in an adult: a case report. J Med Case Rep. 2016; 10: 75.

Muñoz Espinosa LE. Colestasis y hepatitis autoinmune. Rev Gastroenterol Méx. 2013; 78(Supl 1): 98-100.

Chiang JL. Bile acid metabolism and signaling. Compr Physiol. 2013; 3(3): 1191–1212.

Khan MR, Tariq J, Raza R, Effendi MS. Portal hypertensive biliopathy: review of pathophysiology and management. Trop Gastroenterol. 2012; 33: 173-8.

Ruth Bolier, Oude Elferink RP, Beuers U. Advances in pathogenesis and treatment of pruritus. Clin Liver Dis. 2013; 17(2): 319–29.

Chattopadhyay S, Nundy S. Portal biliopathy. World J Gastroenterol. 2012; 18(43): 6177-82.

Hall P, Cash J. What is the real function of the liver function test? Ulster Med J. 2012; 81(1): 30-6

Campos S, Silva N, Carvalho A. A new paradigm in gallstones diseases and marked elevation of transaminases: an observational study. Ann Hepat. 2017; 16(2): 285-90.

Green RM, Flamm S. American Gastroenterological Association technical review on the evaluation of liver chemistry test. Gastroenterology. 2002; 123(4): 1387-84.

Rupp C, Rössler A, Halibasic E, Sauer P, Weiss KH, Friedrich K, et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther. 2014; 40(11-12): 1292–301.

Collier J, Bassendine M. How to respond to abnormal liver function tests. Clin Med (Lond). 2002; 2(5): 406-9.

Alswat K, Al-Harthy N, Mazrani W, Alshumrani G, Jhaveri K, Hirschfield GM. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol. 2012; 107(1): 56–63.

Rogoveanu I, Gheonea DI, Saftoiu A, Ciurea T. The role of imaging methods in identifying the causes of extrahepatic cholestasis. J Gastrointestin Liver Dis. 2006; 15(3): 265-71.

Berzigotti A, Castera L. Update on ultrasound imaging of liver fibrosis. J Hepatol. 2013; 59(1): 180-2.

Schiavon LL, Narciso-Schiavon JL, de Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol. 2014; 20(11): 2854-66.

Popov Y. Mouse model of primary biliary cirrhosis withprogressive fibrosis: are we there yet? Hepatology. 2013; 57(2): 429-31.

Azizi L, Raynal M, Cazejust J, Ruiz A, Menu Y, Arrivé L. MR Imaging of sclerosing cholangitis. Clin Res Hepatol Gastroenterol. 2012; 36(2): 130-8.

Besa C, Cruz JP, Huete A, Cruz F. Portal biliopathy: a multitechnique imaging approach. Abdom Imaging. 2012; 37(1): 83-90.

Sasahira N, Hamada T, Togawa O, Yamamoto R, Iwai T, Tamada K, et al. Multicenter study of endoscopic preoperative biliary drainage for malignant distal biliary obstruction. World J Gastroenterol. 2016; 22(14): 3793-802.

Chathadi KV, Chandrasekhara V, Acosta RD, Decker GA, Early DS, Eloubeidi MA, et al. The role of ERCP in benign diseases of the biliary tract. Gastrointest Endosc. 2015; 81(4): 795-803.

Sharma M, Singh B, Varghese R. Surgical clips in the common bile duct suspected on endoscopic ultrasound and confirmed on endoscopic retrograde cholangiopancreatography. Endosc Ultrasound. 2013; 2(3):157–8.

Singh A, Siddiqui UD. The role of endoscopy in the diagnosis and management of cholangiocarcinoma. J Clin Gastroenterol. 2015; 49(9): 725–37.

Lamarca A, Rigby C, McNamara MG, Hubner RA, Valle JW. Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. World J Gastroenterol. 2016; 22(26): 6065-75.

Ge PS, Hamerski CM, Watson RR, Komanduri S, Cinnor BB, Bidari K, et al. Plastic biliary stent patency in patients with locally advanced pancreatic adenocarcinoma receiving down staging chemotherapy. Gastrointest Endosc. 2015; 81(2): 360-3.

Sung JJ, Jae KM, So YK, Jun HK, Sun YM, Kang HL, et al. Portal biliopathy treated with endoscopic biliary stenting. Clin Mol Hepatol. 2016; 22(1): 172-6.

Chuan X, Peng HL, Xin EH, Ling S, Shu XW, Fu AW. Internal-external percutaneous transhepatic biliary drainage for patients with malignant obstructive jaundice. Asian Pac J Cancer Prev. 2014; 15(21): 9391-4.

Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013; 57(5): 1931–41.

Wu T, Li XP, Xu YJ, Du G, Liu D. Ursodeoxycholic acid pretreatment reduces oral bioavailability of the multiple drug resistance-associated protein 2 substrate baicalin in rats. Planta Med. 2013; 79(17): 1615–9.

Buryova H, Chalupsky K, Zbodakova O, Kanchev I, Jirouskova M, Gregor M, et al. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity. BMC Gastroenterol. 2013; 13(1): 155.

Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015; 62(1 Suppl): 25-37.

Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis andin adequate response to ursodeoxycholic acid. Gastroenterology. 2015; 148(4): 751-61.

Bolier AR, Peri S, Oude Elferink RP, Beuers U. The challenge of cholestatic pruritus. Acta Gastroenterol Belg. 2012; 75(4): 399-404.

Carrion AF, Bhamidimarri KR. Liver transplant for cholestatic liver diseases. Clin Liver Dis. 2013; 17(2): 345-59.

Xiao M, Ji W, Xuan H, Yanling Z, Jiabo W, Ping Z, et al. Large dosage of Chishao in formulae for cholestatic hepatitis: a systematic review and meta-analysis. Evid-Based Complement Alternat Med. 2014 [citado 7 May 2017]; 2014. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060395/

Fu Yq, Hua C, Zhou J, Cheng BR, Zhang J. Protective effects of ginseng total saponins against hepatic ischemia/reperfusion injury in experimental obstructive jaundice rats. Pharm Biol. 2013; 51(12): 1545–51.

Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016; 10(4): 517-36.



Bookmark and Share


Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.